HCV and GBV-C/HGV infection in HIV positive patients in Southern Italy

D. Rendina, E. Vigorita, R. Bonavolta, M. D'onofrio, A. Iura, M. T T Pietronigro, R. Laccetti, G. Bonadies, G. Liuzzi, G. Borgia, P. Formisano, P. Laccetti, G. Portella

Research output: Contribution to journalArticle

Abstract

Flaviviridae-hepatitis C virus (HCV) and GB virus C/hepatitis G virus (GBV-C/HGV) - and human immunodeficiency virus (HIV) frequently show similar modes of transmission. HCV and GBV- C/HGV infection was assessed in 134 consecutive patients with evidence of HIV infection, living in Campania, Italy. Data obtained from this cohort were compared with those obtained from 252 age-and sex-matched HCV infected patients without evidence of HIV infection (HCV control group). Following enzymatic immunoassays, samples were tested for the presence of HCV-RNA by RT-PCR. The HCV-RNA positive sera were genotyped by LiPA procedure. The prevalence of HCV infection in HIV patients was 19.40% and the largest group of HIV-HCV co-infected patients (84.62%) was represented by intravenous drug users (IVDU). The distribution of HCV genotypes in HIV-HCV patients was different, compared to that observed in HCV control group. HCV genotypes la (50%) and 3a (23.08%) were more frequently detected in HIV-HCV patients, compared to HCV control group (5.16 and 5.56% for la and 3a, respectively). Conversely, HCV genotypes lb (55.70%) and 2a/2c (30.26%) were more represented in HCV control group, compared to HIV-HCV patients (15.38 and 0% for lb and 2a/2c, respectively). GBV-C/HGV seroprevalence was 41.04% in HIV patients and 6.54% in healthy control individuals. Differently from HCV, GBV-C/HGV infection did not correlate to a preferential risk behaviour in the HIV cohort. Comparative analysis of HCV and GBV-C/HGV infection indicates that the use of injecting drugs might play a key role in the epidemiology of HCV and, in particular, of la and 3a HCV genotypes, in HIV patients.

Original languageEnglish
Pages (from-to)801-807
Number of pages7
JournalEuropean Journal of Epidemiology
Volume17
Issue number9
DOIs
Publication statusPublished - 2001

Fingerprint

GB virus C
Virus Diseases
Hepacivirus
Italy
HIV
Genotype
Control Groups

Keywords

  • Flaviviridae infection
  • GBV-C/HGV
  • HCV genotypes
  • HIV
  • Southern Italy

ASJC Scopus subject areas

  • Epidemiology

Cite this

Rendina, D., Vigorita, E., Bonavolta, R., D'onofrio, M., Iura, A., Pietronigro, M. T. T., ... Portella, G. (2001). HCV and GBV-C/HGV infection in HIV positive patients in Southern Italy. European Journal of Epidemiology, 17(9), 801-807. https://doi.org/10.1023/A:1015679929395

HCV and GBV-C/HGV infection in HIV positive patients in Southern Italy. / Rendina, D.; Vigorita, E.; Bonavolta, R.; D'onofrio, M.; Iura, A.; Pietronigro, M. T T; Laccetti, R.; Bonadies, G.; Liuzzi, G.; Borgia, G.; Formisano, P.; Laccetti, P.; Portella, G.

In: European Journal of Epidemiology, Vol. 17, No. 9, 2001, p. 801-807.

Research output: Contribution to journalArticle

Rendina, D, Vigorita, E, Bonavolta, R, D'onofrio, M, Iura, A, Pietronigro, MTT, Laccetti, R, Bonadies, G, Liuzzi, G, Borgia, G, Formisano, P, Laccetti, P & Portella, G 2001, 'HCV and GBV-C/HGV infection in HIV positive patients in Southern Italy', European Journal of Epidemiology, vol. 17, no. 9, pp. 801-807. https://doi.org/10.1023/A:1015679929395
Rendina D, Vigorita E, Bonavolta R, D'onofrio M, Iura A, Pietronigro MTT et al. HCV and GBV-C/HGV infection in HIV positive patients in Southern Italy. European Journal of Epidemiology. 2001;17(9):801-807. https://doi.org/10.1023/A:1015679929395
Rendina, D. ; Vigorita, E. ; Bonavolta, R. ; D'onofrio, M. ; Iura, A. ; Pietronigro, M. T T ; Laccetti, R. ; Bonadies, G. ; Liuzzi, G. ; Borgia, G. ; Formisano, P. ; Laccetti, P. ; Portella, G. / HCV and GBV-C/HGV infection in HIV positive patients in Southern Italy. In: European Journal of Epidemiology. 2001 ; Vol. 17, No. 9. pp. 801-807.
@article{1488a84a80ee463bbc98aab558490886,
title = "HCV and GBV-C/HGV infection in HIV positive patients in Southern Italy",
abstract = "Flaviviridae-hepatitis C virus (HCV) and GB virus C/hepatitis G virus (GBV-C/HGV) - and human immunodeficiency virus (HIV) frequently show similar modes of transmission. HCV and GBV- C/HGV infection was assessed in 134 consecutive patients with evidence of HIV infection, living in Campania, Italy. Data obtained from this cohort were compared with those obtained from 252 age-and sex-matched HCV infected patients without evidence of HIV infection (HCV control group). Following enzymatic immunoassays, samples were tested for the presence of HCV-RNA by RT-PCR. The HCV-RNA positive sera were genotyped by LiPA procedure. The prevalence of HCV infection in HIV patients was 19.40{\%} and the largest group of HIV-HCV co-infected patients (84.62{\%}) was represented by intravenous drug users (IVDU). The distribution of HCV genotypes in HIV-HCV patients was different, compared to that observed in HCV control group. HCV genotypes la (50{\%}) and 3a (23.08{\%}) were more frequently detected in HIV-HCV patients, compared to HCV control group (5.16 and 5.56{\%} for la and 3a, respectively). Conversely, HCV genotypes lb (55.70{\%}) and 2a/2c (30.26{\%}) were more represented in HCV control group, compared to HIV-HCV patients (15.38 and 0{\%} for lb and 2a/2c, respectively). GBV-C/HGV seroprevalence was 41.04{\%} in HIV patients and 6.54{\%} in healthy control individuals. Differently from HCV, GBV-C/HGV infection did not correlate to a preferential risk behaviour in the HIV cohort. Comparative analysis of HCV and GBV-C/HGV infection indicates that the use of injecting drugs might play a key role in the epidemiology of HCV and, in particular, of la and 3a HCV genotypes, in HIV patients.",
keywords = "Flaviviridae infection, GBV-C/HGV, HCV genotypes, HIV, Southern Italy",
author = "D. Rendina and E. Vigorita and R. Bonavolta and M. D'onofrio and A. Iura and Pietronigro, {M. T T} and R. Laccetti and G. Bonadies and G. Liuzzi and G. Borgia and P. Formisano and P. Laccetti and G. Portella",
year = "2001",
doi = "10.1023/A:1015679929395",
language = "English",
volume = "17",
pages = "801--807",
journal = "European Journal of Epidemiology",
issn = "0393-2990",
publisher = "Springer Netherlands",
number = "9",

}

TY - JOUR

T1 - HCV and GBV-C/HGV infection in HIV positive patients in Southern Italy

AU - Rendina, D.

AU - Vigorita, E.

AU - Bonavolta, R.

AU - D'onofrio, M.

AU - Iura, A.

AU - Pietronigro, M. T T

AU - Laccetti, R.

AU - Bonadies, G.

AU - Liuzzi, G.

AU - Borgia, G.

AU - Formisano, P.

AU - Laccetti, P.

AU - Portella, G.

PY - 2001

Y1 - 2001

N2 - Flaviviridae-hepatitis C virus (HCV) and GB virus C/hepatitis G virus (GBV-C/HGV) - and human immunodeficiency virus (HIV) frequently show similar modes of transmission. HCV and GBV- C/HGV infection was assessed in 134 consecutive patients with evidence of HIV infection, living in Campania, Italy. Data obtained from this cohort were compared with those obtained from 252 age-and sex-matched HCV infected patients without evidence of HIV infection (HCV control group). Following enzymatic immunoassays, samples were tested for the presence of HCV-RNA by RT-PCR. The HCV-RNA positive sera were genotyped by LiPA procedure. The prevalence of HCV infection in HIV patients was 19.40% and the largest group of HIV-HCV co-infected patients (84.62%) was represented by intravenous drug users (IVDU). The distribution of HCV genotypes in HIV-HCV patients was different, compared to that observed in HCV control group. HCV genotypes la (50%) and 3a (23.08%) were more frequently detected in HIV-HCV patients, compared to HCV control group (5.16 and 5.56% for la and 3a, respectively). Conversely, HCV genotypes lb (55.70%) and 2a/2c (30.26%) were more represented in HCV control group, compared to HIV-HCV patients (15.38 and 0% for lb and 2a/2c, respectively). GBV-C/HGV seroprevalence was 41.04% in HIV patients and 6.54% in healthy control individuals. Differently from HCV, GBV-C/HGV infection did not correlate to a preferential risk behaviour in the HIV cohort. Comparative analysis of HCV and GBV-C/HGV infection indicates that the use of injecting drugs might play a key role in the epidemiology of HCV and, in particular, of la and 3a HCV genotypes, in HIV patients.

AB - Flaviviridae-hepatitis C virus (HCV) and GB virus C/hepatitis G virus (GBV-C/HGV) - and human immunodeficiency virus (HIV) frequently show similar modes of transmission. HCV and GBV- C/HGV infection was assessed in 134 consecutive patients with evidence of HIV infection, living in Campania, Italy. Data obtained from this cohort were compared with those obtained from 252 age-and sex-matched HCV infected patients without evidence of HIV infection (HCV control group). Following enzymatic immunoassays, samples were tested for the presence of HCV-RNA by RT-PCR. The HCV-RNA positive sera were genotyped by LiPA procedure. The prevalence of HCV infection in HIV patients was 19.40% and the largest group of HIV-HCV co-infected patients (84.62%) was represented by intravenous drug users (IVDU). The distribution of HCV genotypes in HIV-HCV patients was different, compared to that observed in HCV control group. HCV genotypes la (50%) and 3a (23.08%) were more frequently detected in HIV-HCV patients, compared to HCV control group (5.16 and 5.56% for la and 3a, respectively). Conversely, HCV genotypes lb (55.70%) and 2a/2c (30.26%) were more represented in HCV control group, compared to HIV-HCV patients (15.38 and 0% for lb and 2a/2c, respectively). GBV-C/HGV seroprevalence was 41.04% in HIV patients and 6.54% in healthy control individuals. Differently from HCV, GBV-C/HGV infection did not correlate to a preferential risk behaviour in the HIV cohort. Comparative analysis of HCV and GBV-C/HGV infection indicates that the use of injecting drugs might play a key role in the epidemiology of HCV and, in particular, of la and 3a HCV genotypes, in HIV patients.

KW - Flaviviridae infection

KW - GBV-C/HGV

KW - HCV genotypes

KW - HIV

KW - Southern Italy

UR - http://www.scopus.com/inward/record.url?scp=0035740151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035740151&partnerID=8YFLogxK

U2 - 10.1023/A:1015679929395

DO - 10.1023/A:1015679929395

M3 - Article

C2 - 12081097

AN - SCOPUS:0035740151

VL - 17

SP - 801

EP - 807

JO - European Journal of Epidemiology

JF - European Journal of Epidemiology

SN - 0393-2990

IS - 9

ER -